Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | +0.19% | -0.31% | +95.49% |
May. 02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
Business Summary
Number of employees: 143
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Rick Scalzo
DFI | Director of Finance/CFO | 38 | 19-11-30 |
John Najim
CTO | Chief Tech/Sci/R&D Officer | 48 | 19-07-31 |
Chief Tech/Sci/R&D Officer | 63 | 20-01-26 | |
Chief Tech/Sci/R&D Officer | 61 | 19-06-27 | |
Wildon Farwell
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-03-03 |
Ashish Dugar
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-07 |
Susanna High
COO | Chief Operating Officer | 56 | 20-06-30 |
Amy Reilly
IRC | Investor Relations Contact | 51 | 20-06-30 |
Daniel Wilson
LAW | General Counsel | 53 | 20-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Hurwitz
BRD | Director/Board Member | 60 | 18-10-31 |
David Lubner
BRD | Director/Board Member | 60 | 20-02-29 |
Dirk Kersten
BRD | Director/Board Member | 49 | 18-10-31 |
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Carlo Incerti
BRD | Director/Board Member | 65 | 22-03-01 |
Chief Tech/Sci/R&D Officer | 61 | 19-06-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 87,382,638 | 86,905,489 ( 99.45 %) | 0 | 99.45 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.49% | 2.27B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- DYN Stock
- Company Dyne Therapeutics, Inc.